The Role of Visfatin in Pregnancy, Complications and Procreation

Journal of Pediatric Biochemistry

Volumn 5, Issue 1, 2015, Pages 2-7

  Marseglia, Lucia ^a   Manti, Sara ^a   D'Angelo, Gabriella ^a   Cuppari, Caterina ^a   Salpietro, Vincenzo ^a   Filippelli, Martina ^a   Chirico, Valeria ^a   Gitto, Eloisa ^a   Salpietro, Carmelo ^a   Arrigo, Teresa ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

breast feeding; gestational diabetes mellitus; newborns; preeclampsia; pregnancy; visfatin

Indexed keywords

ADIPOCYTOKINE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

ADIPOCYTE; APOPTOSIS; BINDING AFFINITY; BREAST FEEDING; DISEASE MARKER; ENDOCRINE DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FETUS DEVELOPMENT; FETUS OUTCOME; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAUTERINE GROWTH RETARDATION; NEWBORN SEPSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERINATAL PERIOD; PREECLAMPSIA; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84951202528     PISSN: 18795390     EISSN: 18795404     Source Type: Journal    
DOI: 10.1055/s-0035-1554783     Document Type: Review

References (73)

1. Mamì C.; Marseglia L.; Manganaro R.; et al. Serum levels of resistin and its correlation with adiponectin and insulin in healthy full term neonates. Early Hum Dev: 2009; 85 1 37 40
2. Rajala M. W.; Scherer P. E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology: 2003; 144 9 3765 3773
3. Arrigo T.; Chirico V.; Salpietro V.; et al. High-mobility group protein B1: a new biomarker of metabolic syndrome in obese children. Eur J Endocrinol: 2013; 168 4 631 638
4. Chirico V.; Cannavò S.; Lacquaniti A.; et al. Prolactin in obese children: a bridge between inflammation and metabolic-endocrine dysfunction. Clin Endocrinol (Oxf): 2013; 79 4 537 544
5. d'Annunzio G.; Vanelli M.; Pistorio A.; et al. Diabetes Study Group of the Italian Society for Pediatric Endocrinology and Diabetes. Insulin resistance and secretion indexes in healthy Italian children and adolescents: a multicentre study. Acta Biomed: 2009; 80 1 21 28
6. Kralisch S.; Bluher M.; Paschke R.; Stumvoll M.; Fasshauer M. Adipokines and adipocyte targets in the future management of obesity and the metabolic syndrome. Mini Rev Med Chem: 2007; 7 1 39 45
7. Samal B.; Sun Y.; Stearns G.; Xie C.; Suggs S.; McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol: 1994; 14 2 1431 1437
8. Fukuhara A.; Matsuda M.; Nishizawa M.; et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science: 2005; 307 5708 426 430
9. Friebe D.; Löffler D.; Schönberg M.; et al. Impact of metabolic regulators on the expression of the obesity associated genes FTO and NAMPT in human preadipocytes and adipocytes. PLoS ONE: 2011; 6 6 e19526
10. Preiss J.; Handler P. Enzymatic synthesis of nicotinamide mononucleotide. J Biol Chem: 1957; 225 2 759 770
11. Revollo J. R.; Grimm A. A.; Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem: 2004; 279 49 50754 50763
12. Rongvaux A.; Andris F.; Van Gool F.; Leo O. Reconstructing eukaryotic NAD metabolism. BioEssays: 2003; 25 7 683 690
13. Revollo J. R.; Grimm A. A.; Imai S. The regulation of nicotinamide adenine dinucleotide biosynthesis by Nampt/PBEF/visfatin in mammals. Curr Opin Gastroenterol: 2007; 23 2 164 170
14. Lin S. J.; Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol: 2003; 15 2 241 246
15. Imai S.; Armstrong C. M.; Kaeberlein M.; Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature: 2000; 403 6771 795 800
16. van der Veer E.; Nong Z.; O'Neil C.; Urquhart B.; Freeman D.; Pickering J. G. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res: 2005; 97 1 25 34
17. Moynihan K. A.; Grimm A. A.; Plueger M. M.; et al. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab: 2005; 2 2 105 117
18. Revollo J. R.; Körner A.; Mills K. F.; et al. Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab: 2007; 6 5 363 375
19. Hug C.; Lodish H. F. Medicine. Visfatin: a new adipokine. Science: 2005; 307 5708 366 367
20. Garten A.; Petzold S.; Körner A.; Imai S.; Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab: 2009; 20 3 130 138
21. Sethi J. K. Is PBEF/visfatin/Nampt an authentic adipokine relevant to the metabolic syndrome? Curr Hypertens Rep: 2007; 9 1 33 38
22. Körner A.; Blüher S.; Kapellen T.; et al. Obesity in childhood and adolescence: a review in the interface between adipocyte physiology and clinical challenges. Hormones (Athens): 2005; 4 4 189 199
23. Kover K.; Tong P. Y.; Watkins D.; et al. Expression and regulation of Nampt in human islets. PLoS ONE: 2013; 8 3 e58767
24. Bełtowski J. Apelin and visfatin: unique beneficial adipokines upregulated in obesity? Med Sci Monit: 2006; 12 6 RA112 RA119
25. Martos-Moreno G. A.; Kratzsch J.; Körner A.; et al. Serum visfatin and vaspin levels in prepubertal children: effect of obesity and weight loss after behavior modifications on their secretion and relationship with glucose metabolism. Int J Obes: 2011; 35 10 1355 1362
26. Mu J.; Feng B.; Ye Z.; et al. Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease. J Nephrol: 2011; 24 2 177 184
27. Ta͆çilar M. E.; Cekmez F.; Meral C.; et al. Evaluation of adipocytokines in obese children with insulin resistance. Turk J Pediatr: 2011; 53 3 269 273
28. Berndt J.; Klöting N.; Kralisch S.; et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes: 2005; 54 10 2911 2916
29. Chen M. P.; Chung F. M.; Chang D. M.; et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab: 2006; 91 1 295 299
30. Moschen A. R.; Kaser A.; Enrich B.; et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol: 2007; 178 3 1748 1758
31. Dahl T. B.; Yndestad A.; Skjelland M.; et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation: 2007; 115 8 972 980
32. Friebe D.; Neef M.; Kratzsch J.; et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (NAMPT)/pre-B cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia: 2011; 54 5 1200 1211
33. Adya R.; Tan B. K.; Chen J.; Randeva H. S. Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation. Diabetes Care: 2008; 31 4 758 760
34. Nowell M. A.; Richards P. J.; Fielding C. A.; et al. Regulation of pre-B cell colony-enhancing factor by STAT-3-dependent interleukin-6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum: 2006; 54 7 2084 2095
35. Jia S. H.; Li Y.; Parodo J.; et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest: 2004; 113 9 1318 1327
36. Iqbal J.; Zaidi M. TNF regulates cellular NAD+ metabolism in primary macrophages. Biochem Biophys Res Commun: 2006; 342 4 1312 1318
37. Ognjanovic S.; Bryant-Greenwood G. D. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol: 2002; 187 4 1051 1058
38. Haider D. G.; Schaller G.; Kapiotis S.; Maier C.; Luger A.; Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia: 2006; 49 8 1909 1914
39. López-Bermejo A.; Chico-Julià B.; Fernàndez-Balsells M.; et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes: 2006; 55 10 2871 2875
40. Mastorakos G.; Valsamakis G.; Papatheodorou D. C.; et al. The role of adipocytokines in insulin resistance in normal pregnancy: visfatin concentrations in early pregnancy predict insulin sensitivity. Clin Chem: 2007; 53 8 1477 1483
41. Kendal-Wright C. E.; Hubbard D.; Bryant-Greenwood G. D. Chronic stretching of amniotic epithelial cells increases pre-B cell colony-enhancing factor (PBEF/visfatin) expression and protects them from apoptosis. Placenta: 2008; 29 3 255 265
42. Cekmez F.; Canpolat F. E.; Cetinkaya M.; et al. Diagnostic value of resistin and visfatin, in comparison with C-reactive protein, procalcitonin and interleukin-6 in neonatal sepsis. Eur Cytokine Netw: 2011; 22 2 113 117
43. van Aerde J. E.; Wilke M. S.; Feldman M.; Clandinin M. T. Chapter 42, Accretion of Lipid in the Fetus and Newborn. In: Polin R. A.; Fox W. W.; Abman S. H.; eds. Fetal and Neonatal Physiology. 4th ed. Philadelphia, PA Elsevier Saunders: 2011; 454 469
44. Blanco C. L.; Baillargeon J. G.; Morrison R. L.; Gong A. K. Hyperglycemia in extremely low birth weight infants in a predominantly Hispanic population and related morbidities. J Perinatol: 2006; 26 12 737 741
45. Mazaki-Tovi S.; Romero R.; Kusanovic J. P.; et al. Visfatin in human pregnancy: maternal gestational diabetes vis-à-vis neonatal birthweight. J Perinat Med: 2009; 37 3 218 231
46. Lihn A. S.; Pedersen S. B.; Richelsen B. Adiponectin: action, regulation and association to insulin sensitivity. Obes Rev: 2005; 6 1 13 21
47. Mamì C.; Manganaro R.; Marseglia L.; Saitta G.; Gemelli M.; Martino F. Plasma leptin, insulin, and neuropeptide Y response to feeding in newborn infants. Arch Dis Child Fetal Neonatal Ed: 2006; 91 5 F389
48. Mamì C.; Manganaro R.; Saitta G.; Marseglia L.; Martino F.; Gemelli M. Plasma leptin, insulin, and neuropeptide Y concentrations in infants. Arch Dis Child Fetal Neonatal Ed: 2005; 90 1 F86 F87
49. Meral C.; Cekmez F.; Pirgon O.; et al. The relationship between serum visfatin, adiponectin, and insulin sensitivity markers in neonates after birth. J Matern Fetal Neonatal Med: 2011; 24 1 166 170
50. Krzyzanowska K.; Krugluger W.; Mittermayer F.; et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci (Lond): 2006; 110 5 605 609
51. Mazaki-Tovi S.; Romero R.; Kim S. K.; et al. Could alterations in maternal plasma visfatin concentration participate in the phenotype definition of preeclampsia and SGA? J Matern Fetal Neonatal Med: 2010; 23 8 857 868
52. Malamitsi-Puchner A.; Briana D. D.; Boutsikou M.; Kouskouni E.; Hassiakos D.; Gourgiotis D. Perinatal circulating visfatin levels in intrauterine growth restriction. Pediatrics: 2007; 119 6 e1314 e1318
53. Sethi J. K.; Vidal-Puig A. Visfatin: the missing link between intra-abdominal obesity and diabetes? Trends Mol Med: 2005; 11 8 344 347
54. Ferreira A. F.; Rezende J. C.; Vaikousi E.; Akolekar R.; Nicolaides K. H. Maternal serum visfatin at 11-13 weeks of gestation in gestational diabetes mellitus. Clin Chem: 2011; 57 4 609 613
55. Chan T. F.; Chen Y. L.; Lee C. H.; et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Investig: 2006; 13 5 364 367
56. Pagano C.; Pilon C.; Olivieri M.; et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab: 2006; 91 8 3165 3170
57. Zhaoxia L.; Ying W.; Danqing C. Changes in visfatin levels after oral glucose tolerance test in women with gestational diabetes mellitus. Diabetes Res Clin Pract: 2012; 96 3 e76 e79
58. Fasshauer M.; Blüher M.; Stumvoll M.; Tönessen P.; Faber R.; Stepan H. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function. Clin Endocrinol (Oxf): 2007; 66 3 434 439
59. Harrington T. A.; Thomas E. L.; Frost G.; Modi N.; Bell J. D. Distribution of adipose tissue in the newborn. Pediatr Res: 2004; 55 3 437 441
60. López-Bermejo A.; de Zegher F.; Díaz-Silva M.; Vicente M. P.; Valls C.; Ibáñez L. Cord serum visfatin at term birth: maternal smoking unmasks the relation to foetal growth. Clin Endocrinol (Oxf): 2008; 68 1 77 81
61. Yanni D.; Darendeliler F.; Bas F.; Kucukemre Aydin B.; Coban A.; Ince Z. The role of leptin, soluble leptin receptor, adiponectin and visfatin in insulin sensitivity in preterm born children in prepubertal ages. Cytokine: 2013; 64 1 448 453
62. Giapros V. I.; Kiortsis D. N.; Evagelidou E. N.; et al. Visfatin levels in prepubertal children born small or large for gestational age. Horm Metab Res: 2012; 44 2 135 139
63. Cekmez F.; Canpolat F. E.; Pirgon O.; et al. Adiponectin and visfatin levels in extremely low birth weight infants; they are also at risk for insulin resistance. Eur Rev Med Pharmacol Sci: 2013; 17 4 501 506
64. Ma Y.; Cheng Y.; Wang J.; Cheng H.; Zhou S.; Li X. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Diabetes Res Clin Pract: 2010; 90 1 60 65
65. Yonezawa T.; Haga S.; Kobayashi Y.; Takahashi T.; Obara Y. Visfatin is present in bovine mammary epithelial cells, lactating mammary gland and milk, and its expression is regulated by cAMP pathway. FEBS Lett: 2006; 580 28-29 6635 6643
66. Bienertová-Vašků J.; Bienert P.; Zlámal F.; et al. Visfatin is secreted into the breast milk and is correlated with weight changes of the infant after the birth. Diabetes Res Clin Pract: 2012; 96 3 355 361
67. Sibai B.; Dekker G.; Kupferminc M. Pre-eclampsia. Lancet: 2005; 365 9461 785 799
68. Fasshauer M.; Waldeyer T.; Seeger J.; et al. Serum levels of the adipokine visfatin are increased in pre-eclampsia. Clin Endocrinol (Oxf): 2008; 69 1 69 73
69. Hu W.; Wang Z.; Wang H.; Huang H.; Dong M. Serum visfatin levels in late pregnancy and pre-eclampsia. Acta Obstet Gynecol Scand: 2008; 87 4 413 418
70. Ferreira A. F.; Rezende J. C.; de Cassia C Oliveira R.; Akolekar R.; Nicolaides K. H. Maternal serum visfatin at 11-13 weeks' gestation in preeclampsia. J Hum Hypertens: 2013; 27 4 261 264
71. Milovanov A. P.; Sidorova I. S.; Solonitsyn A. N.; Borovkova E. I. Immunohistochemical evaluation of the distribution of vascular endothelial growth factor in the placenta, placental bed in normal pregnancy and in women with preeclampsia [in Russian]. Arkh Patol: 2008; 70 3 12 15
72. Kim S. C.; Park M. J.; Joo B. S.; Joo J. K.; Suh D. S.; Lee K. S. Decreased expressions of vascular endothelial growth factor and visfatin in the placental bed of pregnancies complicated by preeclampsia. J Obstet Gynaecol Res: 2012; 38 4 665 673
73. Demir B. C.; Atalay M. A.; Ozerkan K.; Doster Y.; Ocakoglu G.; Kucukkomurcu S. Maternal adiponectin and visfatin concentrations in normal and complicated pregnancies. Clin Exp Obstet Gynecol: 2013; 40 2 261 267